Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19)
specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or
resistant Diffuse Large B Cell Lymphoma (DLBCL) to assess the safety and efficacy of this
strategy as a bridge to allogeneic transplantation.